June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Systemic and Ocular Manifestations of Anti-MOG
Author Affiliations & Notes
  • Alexis O'Neil
    Ophthalmology, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
  • Hong-An Nguyen
    Ophthalmology, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
    Vision Research Centre, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
  • Carolina Rush
    Neurology, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
  • Rustum Karanjia
    Ophthalmology, University of Ottawa Faculty of Medicine, Ottawa, Ontario, Canada
    Dohney Eye Institute, California, United States
  • Footnotes
    Commercial Relationships   Alexis O'Neil None; Hong-An Nguyen None; Carolina Rush None; Rustum Karanjia None
  • Footnotes
    Support  International Foundation of Optic Nerve Disease (IFOND), University Medical Research Fund (UMRF)
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 1584 – A0373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alexis O'Neil, Hong-An Nguyen, Carolina Rush, Rustum Karanjia; Systemic and Ocular Manifestations of Anti-MOG. Invest. Ophthalmol. Vis. Sci. 2022;63(7):1584 – A0373.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : There is limited data available for the Canadian adult population diagnosed with anti-MOG. The goal of this study was to increase the understanding of the ophthalmic and neurological manifestations of anti-MOG disease in adults living in a Canadian setting through a retrospective/prospective chart review. With more information on the disease, clinicians can better identify these patients, understand the disease progression, and manage treatment options.

Methods : Data from standard of care ophthalmic and neurological assessments was collected over a 1-year period for patients who were diagnosed with Anti-MOG disease. Data collected includes patient demographics, ophthalmic assessment, neurological assessment, MRI and bloodwork results.
Correlation analysis was made between titer of MOG antibody and objective quantified ophthalmic findings, including electro-diagnostic results, MRI imaging, OCT imaging, and ophthalmic and neurological examination results.

Results : Five patients who were diagnosed with Anti-MOG have been tested. Of these, 60% were female and 40% were male, with ages ranging from 18 to 63 years old. On ocular examination the majority of eyes had normal visual acuity (60%). The remaining eyes had, 20/30, 20/50, hand motion and light perception vision (one eye each, 3 patients). On fundus examination, half the eyes showed signs of optic atrophy on RNFL testing. Vision loss was asymmetric as evidence by a relative afferent pupillary defect in the two patients with decreased vision. In patients affected with Anti-MOG with decreased visual acuity, pattern Visual Evoked Potentials were significantly reduced in amplitude. Other than the initial optic neuritis, one patient experienced no additional neurological effects, while the others experienced scintillating scotomas, recurrent mild paresthesia of both legs, and seizures. The MRIs displayed hyperintense T2 abnormalities in all patients.

Conclusions : The initial results of this study match existing literature for anti-MOG disease. Optic nerve atrophy is a commonly found ocular sign in patients with anti-MOG. Interestingly, patients were found to have decreased VEP amplitudes but normal inner and outer retinal function. The study recruitment is ongoing.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×